Phase 4 N=15 Pharmacokinetics of Single-Dose Liposomal Bupivacaine in Surgeon Performed Intercostal Nerve Blocks
Thoracic
Primary: Tmax, or the Time Until the Maximum Concentration — 24 Hours
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=23 Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy
Bile Acid Malabsorption · Cholelithiasis
Primary: Change in Stimulated Fibroblast Growth Factor 19 (FGF19) From Baseline Before Versus Post Cholecystectomy — 81; 186 pg per mL — p=0.03
Phase 4 N=24 Testosterone for Peripheral Vascular Disease
Hypogonadism · Peripheral Vascular Disease · Type 2 Diabetes
Primary: Change in Arterial Stiffness — 15.02; 15.08; 14.08; 16.12 index β
Phase 4 N=57 Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa
Depression
Primary: Change in Functional Corticostriatal Connectivity — 0.10; 0.04; 0.07; 0.00 Z-score
Phase 4 N=20 The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold
Healthy
Primary: Hot and Cold Thermal Sensory Threshold for Pain at Baseline in Degrees Celsius. — 43.93; 43.0; 14.81; 13.33 degrees Celsius — p=.47
Phase 4 N=54 Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures
Partial Onset Seizures · Secondarily Generalized Seizures · Primary Generalized Tonic-Clonic Seizures
Primary: Percentage of Participants Remaining on Perampanel Treatment at 3 Months After the Initiation of Treatment — 85.2 percentage of participants
Phase 4 N=152 Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout
Gout
Primary: Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 — 71.0; 38.5 percentage of participants — p=< 0.0001
Phase 4 N=140 Intravenous Dexamethasone on Supraclavicular Brachial Plexus Block for Shoulder Arthroscopy
Shoulder Arthroscopy · Pain
Primary: Duration of Analgesia From a Supraclavicular Block Performed for Shoulder Arthroscopy — 17.4; 22.7; 20.2; 19.8 Hours
Phase 4 N=78 A Novel Analgesia Technique for ACL Reconstruction
Anterior Cruciate Ligament Injury
Primary: Pain While at Rest — 3.84; 3.95 score on a scale
Phase 4 N=87 Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)
Multiple Sclerosis (MS)
Primary: The Time From Randomization to the First Demyelinating Event (Acute or Development of an Initial Symptom Resulting in a Progressive Clinical Course) — 89.69; 77.81 weeks
Phase 4 N=50 Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users
Alcohol Dependence · Alcohol Use Disorder
Primary: Number of Heavy Drinking Days — 62; 0 days
Phase 4 N=202 A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
Acne Vulgaris
Primary: Absolute Change From Baseline in Facial Total Lesion Counts to Week 12 — -69.1; -48.1 Lesion counts
Phase 4 N=20 Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause"
Perimenopausal Disorder · Depression
Primary: Change in Frontostriatal Reactivity to Reward During MID fMRI Task — .0704; .0475; .0623; .0280 percent signal change — p=0.53
Phase 4 N=120 Blue Light Therapy of C. Acnes
Acne
Primary: Number of Participants With C. Acnes Bacterium Culture After Treatment — 20; 20; 16 Participants
Phase 4 N=57 Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes
Diabetic Ketoacidosis · Type 1 Diabetes Mellitus
Primary: Rate of Rebound Hyperglycemia — 20; 18 Participants